Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.3 , No. 3, Publication Date: Jun. 29, 2016, Page: 37-44
 is complicated and poorly reproducible due to limited intestinal absorption and low bioavailability of chocolate bioactives. Cocoa polyphenols have low intestinal absorption rate which translates into low bioavailability. The effect of newly developed (Lycotec Ltd, Cambridge, United Kingdom) lycosome formulation of DC on pharmacokinetics and pharmacodynamics of cocoa bioactives has been studied in 15 clinically healthy Caucasian volunteers (7 men and 8 women, aged from 23 to 65 years) clinically healthy volunteers were enrolled for the double-blind cross-over trial. Coco-Lycosome chocolate was compared with traditional dark chocolate. Pharmacokinetics and biochemical parameters were assessed during the first three hours following ingestion DC specimens. It was shown that implementation of Coco-Lycosome technology increases bioavailability of chocolate catechins without affecting the level of absorption of theobromine or caffeine. It was found that lycopene could provide a level of protection to catechins in the chocolate matrix which could result in an increase in their bioavailability of up to 10 – 20 fold. The variation in this increase among participants was thought to be related to their individual metabolic limitations in processing ingested catechins. Theobromine and caffeine levels in serum were not affected. The elevated level of catechins in blood after consumption of Coco-Lycosome chocolate was accompanied by augmentation of anti-inflammatory and antioxidant properties. Therefore incorporation of lycopene in the DC matrix and subsequent formation of Coco-lycosomes increases the bioavailability of chocolate catechins and has enhanced anti-inflammatory effect. The possible benefits of this technology, which could help to create more potent catechin-rich chocolate products, are discussed in this paper.&picture=http://www.aascit.org/aascit/decorators/img/journal/907.jpg)
| [1] | Ivan M. Petyaev, Lycotec Ltd, Granta Park Campus, Cambridge, United Kingdom. |
| [2] | Dmitry Pristenskiy, Lycotec Ltd, Granta Park Campus, Cambridge, United Kingdom. |
| [3] | Tatyana Bandaletova, DiagNodus Ltd, Babraham Research Campus, Cambridge, United Kingdom. |
| [4] | Natalia E. Chalyk, Institute of Cardiology, Chernyshevskogo Str, Saratov, Russia. |
| [5] | Victor Klochkov, Institute of Cardiology, Chernyshevskogo Str, Saratov, Russia. |
| [6] | Nigel H. Kyle, Lycotec Ltd, Granta Park Campus, Cambridge, United Kingdom. |
Despite of numerous health effects a medicinal use of dark chocolate (DC) is complicated and poorly reproducible due to limited intestinal absorption and low bioavailability of chocolate bioactives. Cocoa polyphenols have low intestinal absorption rate which translates into low bioavailability. The effect of newly developed (Lycotec Ltd, Cambridge, United Kingdom) lycosome formulation of DC on pharmacokinetics and pharmacodynamics of cocoa bioactives has been studied in 15 clinically healthy Caucasian volunteers (7 men and 8 women, aged from 23 to 65 years) clinically healthy volunteers were enrolled for the double-blind cross-over trial. Coco-Lycosome chocolate was compared with traditional dark chocolate. Pharmacokinetics and biochemical parameters were assessed during the first three hours following ingestion DC specimens. It was shown that implementation of Coco-Lycosome technology increases bioavailability of chocolate catechins without affecting the level of absorption of theobromine or caffeine. It was found that lycopene could provide a level of protection to catechins in the chocolate matrix which could result in an increase in their bioavailability of up to 10 – 20 fold. The variation in this increase among participants was thought to be related to their individual metabolic limitations in processing ingested catechins. Theobromine and caffeine levels in serum were not affected. The elevated level of catechins in blood after consumption of Coco-Lycosome chocolate was accompanied by augmentation of anti-inflammatory and antioxidant properties. Therefore incorporation of lycopene in the DC matrix and subsequent formation of Coco-lycosomes increases the bioavailability of chocolate catechins and has enhanced anti-inflammatory effect. The possible benefits of this technology, which could help to create more potent catechin-rich chocolate products, are discussed in this paper.
Keywords
Chocolate Catechins, Lycopene, Lycosome, Inflammation, Pharmacokinetics
Reference
| [01] | Kerimi A, Williamson G. The cardiovascular benefits of dark chocolate. Vascul Pharmacol. 2015 Aug; 71: 11-5 |
| [02] | Katz DL, Doughty K, Ali A. Cocoa and chocolate in human health and disease. Antioxid Redox Signal. 2011 Nov 15; 15 (10): 2779-811. |
| [03] | Şentürk T, Günay Ş. The mysterious light of dark chocolate. Turk Kardiyol Dern Ars. 2015 Mar; 43 (2): 199-207. |
| [04] | Sarriá B, Mateos R, Sierra-Cinos JL, Goya L, García-Diz L, Bravo L. Hypotensive, hypoglycaemic and antioxidant effects of consuming a cocoa product in moderately hypercholesterolemic humans. Food Funct. 2012 Aug; 3 (8): 867-74. |
| [05] | Gossai D, Lau-Cam CA. Assessment of the effect of type of dairy product and of chocolate matrix on the oral absorption of monomericchocolate flavanols in a small animal model. Pharmazie. 2009 Mar; 64 (3): 202-9. |
| [06] | McShea A, Ramiro-Puig E, Munro SB, Casadesus G, Castell M, Smith MA. Clinical benefit and preservation of flavonols in dark chocolate manufacturing. Nutr Rev. 2008 Nov; 66 (11): 630-41. |
| [07] | Ramirez-Sanchez I, Aguilar H, Ceballos G, Villarreal F. (-)-Epicatechin-induced calcium independent eNOS activation: roles of HSP90 and AKT. Mol Cell Biochem. 2012 Nov; 370 (1-2): 141-50. |
| [08] | Grassi D, Desideri G, Necozione S, Ruggieri F, Blumberg JB, Stornello M, Ferri C. Protective effects of flavanol-rich dark chocolate on endothelial function and wave reflection during acute hyperglycemia. Hypertension. 2012 Sep; 60 (3): 827-32. |
| [09] | Gülçin İ. Antioxidant activity of food constituents: an overview. Arch Toxicol. 2012 Mar; 86 (3): 345-91. |
| [10] | Koegler H. Too sweet to be real? Arch Intern Med. 2012 Sep 10; 172 (16): 1270-79. |
| [11] | Shiina Y, Funabashi N, Lee K, Murayama T, Nakamura K, Wakatsuki Y, Daimon M, Komuro I. Acute effect of oral flavonoid-rich dark chocolate intake on coronary circulation, as compared with non-flavonoid white chocolate, by transthoracic Doppler echocardiography in healthy adults. Int J Cardiol. 2009 Jan 24; 131 (3): 424-9. |
| [12] | Flammer AJ, Sudano I, Wolfrum M, Thomas R, Enseleit F, Périat D, Kaiser P, Hirt A, Hermann M, Serafini M, Lévêques A, Lüscher TF, Ruschitzka F, Noll G, Corti R. Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J. 2012 Sep; 33 (17): 2172-80. doi: 10.1093/eurheartj/ehr448. Epub 2011 Dec 15. |
| [13] | Donovan JL, Crespy V, Oliveira M, Cooper KA, Gibson BB, Williamson G. (+)-Catechin is more bioavailable than (-)-catechin: relevance to the bioavailability of catechin from cocoa. Free Radic Res. 2006 Oct; 40 (10): 1029-34. |
| [14] | CAROTENOID PARTICLES AND USES THEREOF. GB Patent Application No. 1101669.8, PCT/GB2012/000075, 25.01.2012. |
| [15] | Cooper KA, Campos-Giménez E, Jiménez Alvarez D, Nagy K, Donovan JL, Williamson G. Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. Agric Food Chem. 2007 Apr 18; 55 (8): 2841-7. |
